Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZA®, for the treatment of Chronic Idiopathic Constipation in adults.

 

May 8, 2008
Sucampo Pharmaceuticals Reports Financial Results for the First Quarter of 2008

May 1, 2008
Sucampo Pharmaceuticals to Host First Quarter 2008 Financial Results Conference Call on May 8, 2008

Apr 29, 2008
Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZAŽ for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women